» Articles » PMID: 23998966

Structural Characterization of Iron Oxide/hydroxide Nanoparticles in Nine Different Parenteral Drugs for the Treatment of Iron Deficiency Anaemia by Electron Diffraction (ED) and X-ray Powder Diffraction (XRPD)

Overview
Specialty Chemistry
Date 2013 Sep 4
PMID 23998966
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Drug products containing iron oxide and hydroxide nanoparticles (INPs) are important for the treatment of iron deficiency anaemia. Pharmaceuticals prepared by the complexation of different kinds of INPs and carbohydrates have different physicochemical and biopharmaceutic characteristics. The increasing number of parenteral non-biological complex drugs (NBCD) containing iron requires physicochemical methods for characterization and enabling of cross comparisons. In this context the structure and the level of crystallinity of the iron phases may be connected to the in vitro and in vivo dissolution rates, which etiologically determine the therapeutic and toxic effects. X-ray powder diffraction (XRPD) and electron diffraction (ED) methods were used in order to investigate the nine different parenteral iron formulations Ferumoxytol (Feraheme(®)), sodium ferric gluconate sucrose (Ferrlecit(®)), iron sucrose (Venofer(®)), low molecular weight iron dextran (CosmoFer(®)), low molecular weight iron dextran (Infed(®)), high molecular weight iron dextran (Ironate(®)), high molecular weight iron dextran (Dexferrum(®)), iron carboxymaltose (Ferinject(®)) and iron isomaltoside 1000 (Monofer(®)). The iron phase in CosmoFer(®), Ferinject(®), Monofer(®), Infed(®), Ironate(®) and Dexferrum(®) was identified as Akaganéite/Akaganéite-like (β-FeOOH), with low amounts of chloride. By combining results of both methods the iron oxide in Feraheme(®) was identified as Magnetite (Fe3O4) with spinel-like structure. Ferrlecit(®) and Venofer(®) were difficult to analyze due to the low degree of crystallinity, but the iron phase seems to fit Lepidocrocite/Lepidocrocite-like (γ-FeOOH) or an amorphous kind of structure. The structural information on the type of iron oxide or hydroxide together with the particle size allows predicting the stability of the different complexes including their labile iron content. The combination of ED and XRPD methods is a very helpful approach especially for structural analysis of nanoscopic or low crystalline materials.

Citing Articles

Nanomedicine Therapies for Pediatric Diseases.

Yang S, Aggarwal K, Jurczyszak J, Brown N, Sridhar S Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(5):e1996.

PMID: 39420230 PMC: 11493394. DOI: 10.1002/wnan.1996.


Geometry and Surface Area Optimization in Iron Oxide Nanoparticles for Enhanced Magnetic Properties.

Lavin Flores A, Medina-Berrios N, Pantoja-Romero W, Berrios Plaza D, Kisslinger K, Beltran-Huarac J ACS Omega. 2024; 9(30):32980-32990.

PMID: 39100356 PMC: 11292628. DOI: 10.1021/acsomega.4c03988.


Iron nanoparticles as food additives and food supplements, regulatory and legislative perspectives.

Chavarria-Fernandez S, Jimenez-Alvarado R, Santos-Lopez E, Hernandez-Hernandez A, Carino-Cortes R Food Sci Biotechnol. 2024; 33(6):1295-1305.

PMID: 38585565 PMC: 10992046. DOI: 10.1007/s10068-024-01518-y.


Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial.

Kassianides X, Allgar V, Macdougall I, Kalra P, Bhandari S Sci Rep. 2022; 12(1):6853.

PMID: 35477731 PMC: 9046378. DOI: 10.1038/s41598-022-10717-8.


Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.

Funk F, Fluhmann B, Barton A Int J Mol Sci. 2022; 23(4).

PMID: 35216261 PMC: 8878488. DOI: 10.3390/ijms23042140.